Vasa Therapeutics is a San Diego-based, private biotechnology company founded in 2019, specializing in the discovery and development of therapeutics targeting the pathophysiology of cardiovascular aging.
The company currently has three active preclinical programs:
1. VS-041 is the first personalized medicine-based treatment of HFpEF, demonstrating robust reduction of cardiac fibrosis in a preclinical HFpEF model and inhibiting the release of signaling collagen fragments, such as PRO-C6, which are biomarkers of worse outcomes in HFpEF patients. The phase 1 clinical trial of VS-041 is scheduled for 2024.
2. Long-acting apelin peptide analogs are being developed for combination treatment with incretins in obesity patients at risk for skeletal muscle loss or cardiovascular disease. As a monotherapy, long-acting apelin agonists could also be beneficial in muscle atrophy, heart failure, chronic kidney disease, and peripheral artery disease.
3. The company is also working on a best-in-class inhibitor of CamKIId for heart failure and life-threatening arrhythmias.
The latest milestone for Vasa Therapeutics is a $6.00MSeed Round investment at 03 January 2024, led by NuFund Venture Group, SeedFolio, and Orphinic Scientific.
